Live tape
Top 8, mentions 7d10,080TSLA2,070 mentions▲ +0.05GOOGL1,610 mentions▲ +0.04NVDA1,232 mentions▲ +0.07CRWV1,218 mentions▲ +0.03SPCX1,107 mentions▲ +0.07QQQ1,076 mentions▲ +0.04META891 mentions▲ +0.05NBIS876 mentions▲ +0.05

Equity · Healthcare

IMNM

NASDAQ

Immunome, Inc.

$22.31 +0.52% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for IMNM to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $2.5B
52-week range $8 – $27
Avg volume 333.7K

as of Jul 17, 2026

IMNM insider trades

SEC Form 4 · last 90 days · newest reported trade 11 Sep 2026
Open-market buys 0
Open-market sells 7
Net sold $5.75M
Non-trade filings 10
Date Insider Type Shares Value
11 Sep 2026 Higgins Jack Chief Scientific Officer Sell 13,200 $334K
12 Aug 2026 Barchas Isaac Director Sell 11,048 $301K
11 Aug 2026 Barchas Isaac Director Sell 62,291 $1.63M
10 Aug 2026 Barchas Isaac Director Sell 10,125 $264K
07 Aug 2026 Barchas Isaac Director Sell 15,248 $397K
06 Aug 2026 Barchas Isaac Director Sell 20,840 $543K
04 Aug 2026 Horn Kinney CHIEF BUSINESS OFFICER Sell 90,616 $2.27M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
11 Sep 2026 Higgins Jack Chief Scientific Officer Option exercise 18,000 $24K
11 Sep 2026 Higgins Jack Chief Scientific Officer Gift 8,800
04 Aug 2026 Horn Kinney CHIEF BUSINESS OFFICER Option exercise 90,616 $1.08M
23 Jul 2026 Higgins Jack Chief Scientific Officer Award 38,250
23 Jul 2026 Horn Kinney CHIEF BUSINESS OFFICER Award 31,250
23 Jul 2026 SIEGALL CLAY B President and CEO Award 180,000
23 Jul 2026 Stoneman Sandra G. CHIEF LEGAL OFFICER & GC Award 38,250
23 Jul 2026 Rosett Max Chief Financial Officer Award 47,250
23 Jul 2026 Lechleider Robert Chief Medical Officer Award 54,000
23 Jul 2026 Tsai Philip Chief Technical Officer Award 38,250

IMNM reported financials

SEC EDGAR XBRL SEC EDGAR

IMNM reported revenue of $6.9M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$212.4M.

Figure Reported Period
Revenue $6.9M 31 Dec 2025 fiscal year
Net income −$212.4M 31 Dec 2025 fiscal year
Diluted EPS −$2.43 31 Dec 2025 fiscal year
Total assets $565.4M 30 Jun 2026 at period end
Total equity $525.1M 30 Jun 2026 at period end

IMNM earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.65 —
31 Mar 2026 Q1 2026 −$0.48 —
31 Dec 2025 FY 2025 −$2.43 $7M
30 Sep 2025 Q3 2025 −$0.65 —
30 Jun 2025 Q2 2025 −$0.50 $4M
31 Mar 2025 Q1 2025 −$0.52 $3M
31 Dec 2024 FY 2024 −$5.00 $9M
30 Sep 2024 Q3 2024 −$0.78 $3M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

IMNM institutional holders

SEC Form 13F SEC EDGAR

6 of the 45 institutional funds we track reported a IMNM position for the quarter ended 30 Jun 2026 — a combined $22.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Marshall Wace Trimmed −66.2% shares 500,537 $10.6M
Renaissance Technologies Added +264.4% shares 251,102 $5.3M
Citadel Advisors Added +179.4% shares 224,079 $4.7M
Baker Bros. Advisors New position 55,306 $1.2M
Two Sigma Investments New position 23,941 $507K
AQR Capital Management Trimmed −37.1% shares 11,780 $250K
Balyasny Asset Management Exited
Millennium Management Exited

IMNM fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 4,100 shares of IMNM failed to deliver (about $90K).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 4,100 $90K 0.004%
22 Sep 2026 37 $928 <0.001%
18 Sep 2026 107 $3K <0.001%
11 Sep 2026 4,036 $101K 0.004%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings